This document discusses the challenges of implementing consistent infection prevention and control (IPC) standards across New Zealand's public health sector. It notes the lack of national standards and real-time data makes it difficult to assess performance, determine necessary interventions, and support clinical decision-making. Healthcare-associated infections impact patient safety and outcomes while increasing costs. The document advocates achieving a national IPC management system using a common software platform called ICNet to standardize data collection, facilitate real-time reporting and analysis, and enable quality improvement activities aimed at reducing infections like surgical site infections. Progress includes ICNet's adoption in several districts and a national surgical site infection monitoring program, though continued coordination and prioritization is needed to fully realize this vision.
Infographic: A Day in the Life of Infection PreventionistsQ-Centrix
A look at a day in the life of a hospital Infection Preventionist (IP). As IPs' roles expand, their hectic day includes making rounds on the hospital floor, enforcing procedures, educating staff, providing proactive counsel...and sometimes spending 5+ hours/day collecting and reporting data to federal health agencies.
.
IMS Health Real-World Evidence Solutions at ISPOR November 2015IMSHealthRWES
Welcome to the IMS Health Real-World Evidence (RWE) Solutions program of activities at the forthcoming ISPOR 18th Annual European Congress in Milan. We invite you to join us at more than 70 presentations that spotlight exciting innovations and applications of outcomes research and RWE. And please visit us at our booth to learn more about our pioneering efforts including the e360TM technology suite, RWD Catalogue with 1,800+ data sources identified, and the newly launched RWE Dictionary. Full details of our ISPOR schedule can be found in the brochure.
Infographic: A Day in the Life of Infection PreventionistsQ-Centrix
A look at a day in the life of a hospital Infection Preventionist (IP). As IPs' roles expand, their hectic day includes making rounds on the hospital floor, enforcing procedures, educating staff, providing proactive counsel...and sometimes spending 5+ hours/day collecting and reporting data to federal health agencies.
.
IMS Health Real-World Evidence Solutions at ISPOR November 2015IMSHealthRWES
Welcome to the IMS Health Real-World Evidence (RWE) Solutions program of activities at the forthcoming ISPOR 18th Annual European Congress in Milan. We invite you to join us at more than 70 presentations that spotlight exciting innovations and applications of outcomes research and RWE. And please visit us at our booth to learn more about our pioneering efforts including the e360TM technology suite, RWD Catalogue with 1,800+ data sources identified, and the newly launched RWE Dictionary. Full details of our ISPOR schedule can be found in the brochure.
Accelerating Patient Care with Real World EvidenceCitiusTech
Life sciences and pharma companies are evolving their strategies to utilize Real World Data (RWD) to demonstrate value of pharmaceutical and medical device innovations. Technology advancements at the point of care and improvements in data collection strategies have led to a significant increase in the availability of RWD in healthcare
Real World Evidence (RWE) can provide actionable patient insights and accelerates time to market of new medical products in order to gain competitive advantage
With the emergence of wearable technologies, Internet of Things (IOT), Cognitive Computing, Genomics, Blockchain, etc., future RWE data sources will become more diverse and extensive. This document introduces the concept of Real World Evidence studies in healthcare, describes the various data sources for performing real world analytics and illustrates the role of RWE in better patient care. It then summarizes challenges faced while performing RWE analytics with respect to regulatory compliance, data accessibility and sharing, analysis reporting, costs etc.
Leveraging Analytics to Identify High Risk PatientsCitiusTech
A predictive analytics platform can help healthcare providers identify which patients and team members could be at the highest risk for severe illness / hospitalization.
Big Data and VistA Evolution, Theresa A. Cullen, MD, MSBrian Ahier
Presentation to Open Source Electronic Health Record Alliance (OSEHRA) Architecture Work Group by Theresa A. Cullen, MD, MS
Chief Medical Information Officer
Director, Health Informatics
Office of Informatics and Analytics
Veterans Health Administration
Department of Veterans Affairs
The role of real world data and evidence in building a sustainable & efficien...Office of Health Economics
This presentation defines RWD and RWE in the context of digital health, and looks at potential uses for RWD and RWE. It briefly sets out the current landscape in Malaysia and looks at the challenges in using RWE. In particular, the issues of access, governance and ensuring good quality are considered.
2015 Edition Proposed RuleModifications to the ONC Health IT Certification ...Brian Ahier
Presentation to April 7, 2015 Health IT Policy Committee:
2015 Edition Proposed RuleModifications to the ONC Health IT Certification Program and 2015 Edition Health IT Certification Criteria
What's Next in RWE_Amy Rudolph_Novartis_mHealth IsraelLevi Shapiro
Overview of the
- Healthcare ecosystem complexity increasing rapidly
- Pharma industry is facing a crisis: trends shaping the industry
- RWE complements RCTs and captures implementation of innovation
- RWE is one component of the integrated evidence needed for stakeholders
- Integrated Evidence: Optimizing patient access
- Integrated Evidence: Label expansion
- Maximizing the value of data requires a scalable platform and expertise
Transforming Post-Acute Care with IMPACTCitiusTech
On October 6, 2014, a bipartisan bill on Improving Medicare Post-Acute Care Transformation (IMPACT) was signed. The IMPACT Act seeks to standardize assessments for vital care issues across the gamut of post-acute care (PAC) providers and builds a framework to ensure that the delivered care is mindful of the patient needs; thereby eliminating the current silo-focused approach to quality measurement and resource utilization.
Medisafe_What's Next in RWE_mHealth IsraelLevi Shapiro
Presentation by Medisafe CEO, Omri Shor, Oct 19, 2021, for the mHealth Israel community.
- Medisafe’s Patient Engagement Platform
- Real World Evidence: Economic Impact for Pharma
- Connecting Pharma to patients
- Case Study: Supporting Patients through Digital Platform
-
Big data, RWE and AI in Clinical Trials made simpleHadas Jacoby
Technology is slowly but surely penetrating the healthcare industry in general and the clinical trials sector in particular. New and advanced solutions offer a variety of possibilities aimed to both improving existing processes and creating new and more efficient ones. And on top of all stands the desire to make clinical trials more patient centric.
In all of this, even though some of the technologies have yet to mature enough to meet the high quality standards necessary, it is important to know them and begin imagining the promise they hold for clinical trials.
Accelerating Patient Care with Real World EvidenceCitiusTech
Life sciences and pharma companies are evolving their strategies to utilize Real World Data (RWD) to demonstrate value of pharmaceutical and medical device innovations. Technology advancements at the point of care and improvements in data collection strategies have led to a significant increase in the availability of RWD in healthcare
Real World Evidence (RWE) can provide actionable patient insights and accelerates time to market of new medical products in order to gain competitive advantage
With the emergence of wearable technologies, Internet of Things (IOT), Cognitive Computing, Genomics, Blockchain, etc., future RWE data sources will become more diverse and extensive. This document introduces the concept of Real World Evidence studies in healthcare, describes the various data sources for performing real world analytics and illustrates the role of RWE in better patient care. It then summarizes challenges faced while performing RWE analytics with respect to regulatory compliance, data accessibility and sharing, analysis reporting, costs etc.
Leveraging Analytics to Identify High Risk PatientsCitiusTech
A predictive analytics platform can help healthcare providers identify which patients and team members could be at the highest risk for severe illness / hospitalization.
Big Data and VistA Evolution, Theresa A. Cullen, MD, MSBrian Ahier
Presentation to Open Source Electronic Health Record Alliance (OSEHRA) Architecture Work Group by Theresa A. Cullen, MD, MS
Chief Medical Information Officer
Director, Health Informatics
Office of Informatics and Analytics
Veterans Health Administration
Department of Veterans Affairs
The role of real world data and evidence in building a sustainable & efficien...Office of Health Economics
This presentation defines RWD and RWE in the context of digital health, and looks at potential uses for RWD and RWE. It briefly sets out the current landscape in Malaysia and looks at the challenges in using RWE. In particular, the issues of access, governance and ensuring good quality are considered.
2015 Edition Proposed RuleModifications to the ONC Health IT Certification ...Brian Ahier
Presentation to April 7, 2015 Health IT Policy Committee:
2015 Edition Proposed RuleModifications to the ONC Health IT Certification Program and 2015 Edition Health IT Certification Criteria
What's Next in RWE_Amy Rudolph_Novartis_mHealth IsraelLevi Shapiro
Overview of the
- Healthcare ecosystem complexity increasing rapidly
- Pharma industry is facing a crisis: trends shaping the industry
- RWE complements RCTs and captures implementation of innovation
- RWE is one component of the integrated evidence needed for stakeholders
- Integrated Evidence: Optimizing patient access
- Integrated Evidence: Label expansion
- Maximizing the value of data requires a scalable platform and expertise
Transforming Post-Acute Care with IMPACTCitiusTech
On October 6, 2014, a bipartisan bill on Improving Medicare Post-Acute Care Transformation (IMPACT) was signed. The IMPACT Act seeks to standardize assessments for vital care issues across the gamut of post-acute care (PAC) providers and builds a framework to ensure that the delivered care is mindful of the patient needs; thereby eliminating the current silo-focused approach to quality measurement and resource utilization.
Medisafe_What's Next in RWE_mHealth IsraelLevi Shapiro
Presentation by Medisafe CEO, Omri Shor, Oct 19, 2021, for the mHealth Israel community.
- Medisafe’s Patient Engagement Platform
- Real World Evidence: Economic Impact for Pharma
- Connecting Pharma to patients
- Case Study: Supporting Patients through Digital Platform
-
Big data, RWE and AI in Clinical Trials made simpleHadas Jacoby
Technology is slowly but surely penetrating the healthcare industry in general and the clinical trials sector in particular. New and advanced solutions offer a variety of possibilities aimed to both improving existing processes and creating new and more efficient ones. And on top of all stands the desire to make clinical trials more patient centric.
In all of this, even though some of the technologies have yet to mature enough to meet the high quality standards necessary, it is important to know them and begin imagining the promise they hold for clinical trials.
NPSF Seminar
Patient Safety Awareness Week
Patient Safety Is a Public Health Issue
Distributed by NPSF for attendees of this web seminar.
I do not own any rights to the content of this presentation and am sharing it for educational purposes only.
Speaker information and credentials are included in the presentation.
Welcome and the National Patient Safety Plan - Dr Mike Durkin (Chair), Director for Patient Safety, NHS England
Presentation from the Patient Safety Collaborative launch event held in London on 14 October 2014
More information at http://www.nhsiq.nhs.uk/improvement-programmes/patient-safety/patient-safety-collaboratives.aspx
OHP's Antonio Boone gave this presentation on different prevention continuum examples at the July meeting of the Prevention Committee of the Philadelphia EMA HIV Integrated Planning Council.
White Paper - Infection Preventionists: Healthcare’s Guardians at the Gate Ne...Q-Centrix
This white paper examines a key player at the front lines of hospitals’ never-ending battles against HAIs –Infection Preventionists (IPs). It briefly explains their varied roles, responsibilities and new challenges, the difficulty in recruiting these highly sought-after experts, and why and how hospitals should be doing more to help overworked and understaffed IPs be successful. Lastly, it covers new technologies and IP support services that can be integrated into hospitals’ infection control practices.
Something In my head for a while, Its probably a little dramatic.
Probably ripe for implementation in India.
The reference by no means are complete, prepared the ppt over an extended period, lost track of references or was too lazy to search for them.
Will me more than glad to add them(references) if provided.
Co-ordinated malaria research for better policy and practice: the role of res...ACT Consortium
Prof. David Schellenberg from the London School of Hygiene & Tropical Medicine presents on behalf of the ACT Consortium at the European Congress on Tropical Medicine and International Health in Basel, Switzerland, 8 September 2015
Mr James Downie, CEO, presented on the topic 'Moving towards value based funding' at the 2017 Activity-Based Funding Conference, hosted by the Health Service Executive, Ireland on 11 May 2017.
EuroBioForum 2013 - Day 1 | Pierre MeulienEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Canada:
Genomics and personalised health in Canada
Dr Pierre Meulien, President and CEO at Genome Canada
=======================================
http://www.eurobioforum.eu
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
The power of information: Achieving a national infection management system
1. The Power of Information
Achieving a National Infection Management System
October 2013
Trevor English
2. Health Sector Challenges
• Challenges in implementing consistent standards for IPC practice and surveillance
have been identified by the the public health sector
• These negatively impact patient safety and outcomes, increase the burdens of cost
and ability for the sector to tackle increased demand on IPC, including concerns with
infections and antimicrobial resistance
• Without methods for defining and measuring current practice and infectious diseases it
is hard to determine how the New Zealand health sector is performing, what
interventions are needed or possible and how they perform
• Local IPC practice is challenged by manual processes, lack of accessibility and
transparency to real time data to support good clinical decisions and patient
management
• Surveillance is challenging due to a lack of national standards and definitions, as
well as the same issues with data accessibility and communication
5. The “return of our old enemies in an
untreatable form”
“The majority of new infectious diseases that have emerged in the
last 40 years are caused by drug-resistant bacteria.”
Ellen Silbergeld, Professor of Environmental Health Sciences and Epidemiology,
Johns Hopkins University’s, Bloomberg School of Public Health
6. What is really at stake?
“Everything about how we live and expect to live. Once upon a time in the
United States — that is, before World War II — infections that we now think
of as easily treatable routinely struck down children, as well as adults in the
prime of life.” Editor Remapping Debate
• More complications
• More hospitalizations and less successful treatment
• More deaths
In the USA each year 1.7 million acquire HAI and there are 99,000 deaths,
according to the Center for Disease Control and Prevention
INFECTION control costs about $76 million a year in Australian public
hospitals but 177,000 patients acquire an infection each year, a Lake
Macquarie academic study has found.
7. Healthcare-associated infections
• Occur in up to 10% of patients receiving healthcare
• NZ Hospital Healthcare Associated Infections estimated cost $137m
pa
• ACC DHB Treatment Injury Claims 2011/12 infection related events
exceeded 900. A subset of SSIs between 2005-2013 cost ACC
$11.4m
• SSI are the second most common type of healthcare-associated
infection (≈20% of all HAI) and are associated with an increased
LOS and cost
• Patients who develop SSI have a 2-to-11 fold higher risk of death
than patients without an SSI
• Surveillance programmes (monitoring and feedback) result in
reduction in SSI
8. The Problem and Solution
The Dream
The Path
The Team The Team
“in New Zealand we don’t have the money
so we have to think”
9. Interventions proven to reduce SSI
• Warm the patient (on the way to theatre)
• Complete the surgical checklist
• Surgical antimicrobial prophylaxis – ‘right drug, right dose,
right time’
• Alcohol-based skin preparation and sterile drapes
• Continue warming the patient
• Double gloves
10. Interventions proven to reduce SSI
• High flow oxygen (≈ 80%)
• Monitoring of blood glucose
• Wound protectors for colorectal surgery
• Antimicrobial sutures for colorectal surgery
• Good surgical technique
• Avoid blood transfusions
11. National SSII Programme
Staged delivery of the programme
– Orthopaedics – total hip and knee joint arthroplasty
(2013)
– Cardiac Surgery (2015)
– Caesarean sections ?
Started with orthopaedics – hip and knee joint
arthroplasties
– 8 ‘development site’ DHB → All 20 DHB by Oct 2013
– Manual collection of data entered via the web into a
central data warehouse hosted at Canterbury DHB
– Central reporting
» Process measures and outcome markers
12. National SSII Programme
CDC NHSN (NNIS) definitions for surgical site infections
• Superficial, deep incisional or organ/joint space
Standardized data collection
– Patient demographics, surgeon details, surgical process and 30
and 90 day follow-up
– Shift from 1 year to 90 day follow-up
Web-based entry into a national database
Multi-discipline collaboration
13. Quality and Safety Markers
QSM = process markers and outcome measures
Process markers
– Best practice processes or interventions known to lead to
reduced harm and improved outcome for patients
• Surgical antimicrobial prophylaxis
• Skin antisepsis
Outcome measures
– Capture the expected reduction in harm, improvement in
health and associated cost savings from interventions put
in place
18. ICNet
• “Off the shelf” software solution
• IPC reporting platform with
modules
– SSI module
– Antimicrobial stewardship
• Currently in use at
– CDHB and West Coast DHB
– TDHB
– HBDHB
• Committed to use
– ADHB
– Waitemata DHB
• National Monitor supporting the
SSII programme
20. IPC staff productivity case study
Same patterns in UK and CDHB
0
1
2
3
4
Data Entry Lab Results Data
Analysis
Patient Data
Search
Management
Reporting
Patient
Surveillance
Pre ICNet Post ICNet
4
2
4
33
2
0.5 0.5
IP&C work pattern changes at Chesterfield Trust have been replicated at CDHB.
Using ICNet to clear administration tasks allows IP&C staff to spend more time and
focus on patient care and infection prevention.
50%+ Reduction
3
1 1 1
21. A clinician’s perspective
Dr Sally Roberts, National Clinical Lead, HQSC
1. ”Infection prevention and control requires accurate readily available data
collected in a timely manner to fully inform decision making. The current means
of capturing data – laborious manual-based methods – does not support this. A
software solution is urgently required.
2. Analysis and reporting needs to be simplified. The current burden of
manual data capture often distracts from data interpretation and does not allow
time for quality improvement activities. The SSII national monitor has shown that
centralised reporting of the data will allow for the delivery of comparable data
across all DHBs.
3. Data collection needs to be consistent nationally. Manual methods allow
for variation in the application of standard definitions, avoidance of capturing all
essential data as it exists in multiple databases and is often person-dependent.
4. We will not be able deliver the HQSC IPC programmes, in particular the SSII
programme, without such a programme as the manual collection of data is not
deemed a high priority for resource-limited IPC services.”
22. To achieve the dream
• National leadership / priority / Plan
• Engaged infection control practitioners
• Coordinated approach to infection control
• Common data systems
• Vendor support
• National reporting and use of the data
• National procurement process
23. We are on the path!
• National leadership / priority / Plan
– Recognition of need
– MoH, HQSC and ESR
– National business case work
• Engaged infection control practitioners
– Workforce demonstrated engagement with SSII
– Generally motivated group
• Coordinated approach to infection control
– Actively collaborate nationally – could enhance
24. We are on the path!
• Common data systems
– ICNet in 6 DHBs, National Monitor in place
– Laboratory providers
• 8 DHB Labs – 6 on or committed to ICNet
• 4 Private lab providers
• Vendor Support
• National reporting and use of the data
– SSII national monitor is in place
– ESR need access to good timely data
• National procurement process
25. The Problem and Solution
The Dream
The Path
The Team The Team
“in New Zealand we don’t have the money
so we have to think”
Editor's Notes
Phase 2, each of the regions will expand to being on their own server, but also users will be expanded from the SSI Forms to full blown ICNet